SecBot SecBot
SECBOTREPLAY Home › Report › AXGN

AXGN · Axogen announced a $200M cash acquisition of BioCircuit Technologies…

Axogen, Inc. · 8-K filed Sep 10, 2026 at 06:02 ET

At the news

BULLISHIMPACT 7/10

8-K filed Sep 10, 2026 at 06:02 ET

Axogen announced a $200M cash acquisition of BioCircuit Technologies (NerveTape sutureless nerve repair device) and simultaneously priced a ~$208.7M common stock offering (4.91M shares at $42.50/sh) to fund the deal. The acquisition adds a differentiated, FDA-cleared sutureless nerve repair platform expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in year one while Axogen remains free cash flow positive. The offering closes Sept 11, 2026; the acquisition is expected to close in Q4 2026 subject to customary conditions including BioCircuit's electronics business spin-out.

  • Axogen to acquire BioCircuit Technologies for $200M in cash at closing
  • Acquisition adds NerveTape, the first FDA-cleared device for sutureless peripheral nerve repair
  • Priced public offering of 4,910,000 shares at $42.50/sh for ~$208.7M gross proceeds
  • Underwriters granted 30-day option for additional 736,500 shares

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access